AUTOLUS THERAPEUTICS PLC's ticker is AUTL and the CUSIP is 05280R100. A total of 70 filers reported holding AUTOLUS THERAPEUTICS PLC in Q4 2022. The put-call ratio across all filers is 0.03 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $394,312 | -85.8% | 214,300 | -85.4% | 0.00% | -89.7% |
| Q4 2022 | $2,782,170 | +100.7% | 1,464,300 | +601.6% | 0.03% | +81.2% |
| Q2 2021 | $1,386,000 | +15.9% | 208,706 | 0.0% | 0.02% | +6.7% |
| Q1 2021 | $1,196,000 | -19.3% | 208,706 | +25.9% | 0.02% | -28.6% |
| Q4 2020 | $1,482,000 | -23.8% | 165,809 | -0.8% | 0.02% | -30.0% |
| Q3 2020 | $1,945,000 | -54.9% | 167,136 | -37.9% | 0.03% | -53.8% |
| Q2 2020 | $4,313,000 | +134.7% | 269,036 | -12.3% | 0.06% | +75.7% |
| Q1 2020 | $1,838,000 | -32.8% | 306,857 | +48.0% | 0.04% | +2.8% |
| Q4 2019 | $2,737,000 | +26.7% | 207,311 | +19.2% | 0.04% | +16.1% |
| Q3 2019 | $2,161,000 | +35.7% | 173,967 | +75.8% | 0.03% | +47.6% |
| Q2 2019 | $1,593,000 | +11.7% | 98,967 | +112.8% | 0.02% | +31.2% |
| Q3 2018 | $1,426,000 | -57.4% | 46,500 | -62.8% | 0.02% | -46.7% |
| Q2 2018 | $3,349,000 | – | 125,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 21,346,829 | $49,738,112 | 74.10% |
| TFG Asset Management GP Ltd | 12,000,000 | $27,960,000 | 5.10% |
| Paradigm Biocapital Advisors LP | 14,406,782 | $33,567,802 | 2.28% |
| Lynx1 Capital Management LP | 1,363,025 | $3,175,848 | 2.10% |
| Deep Track Capital, LP | 15,000,000 | $34,950,000 | 1.35% |
| Affinity Asset Advisors, LLC | 1,992,466 | $4,642,446 | 1.31% |
| DAFNA Capital Management LLC | 928,253 | $2,162,829 | 0.67% |
| Frazier Life Sciences Management, L.P. | 3,746,857 | $8,730,177 | 0.58% |
| ARMISTICE CAPITAL, LLC | 6,900,000 | $16,077,000 | 0.25% |
| Blackstone Inc. | 20,485,611 | $47,731,474 | 0.20% |